Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options

被引：7

作者：

Ampuero, Javier ^{[1
,2
,3
]}

Rajender Reddy, K. ^{[4
]}

Romero-Gomez, Manuel ^{[1
,2
,3
]}

机构：

[1] Univ Seville, Virgen del Rocio Univ Hosp, Interctr Unit Digest Dis, Seville 41018, Spain

[2] Univ Seville, Virgen del Rocio Univ Hosp, CIBERehd, Seville 41018, Spain

[3] Inst Biomed Sevilla, Seville 41018, Spain

[4] Univ Penn, Dept Med, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2016年 / 22卷 / 22期

关键词：

Hepatitis C; Genotype; 3; Sofosbuvir; Daclatasvir; Ledipasvir; DACLATASVIR PLUS SOFOSBUVIR; NS5A INHIBITORS; HCV; RIBAVIRIN; RESISTANCE; CIRRHOSIS; EFFICACY; PEGINTERFERON; INFECTION; REGIMENS;

D O I：

10.3748/wjg.v22.i22.5285

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies. METHODS: (1) PEG-INF-based therapy including sofosbuvir (SOF) + RBV for 12 wk vs SOF + RBV 24 wk; (2) SOF + RBV therapy 12 wk/16 wk vs 24 wk; and (3) the role of RBV in SOF + daclatasvir (DCV) and SOF + ledipasvir (LDV) combinations. This meta-analysis provides robust information with the intention of addressing treatment strategy for hepatitis C virus genotype 3. RESULTS: A combination treatment including SOF + RBV + PEG-IFN for 12 wk notes better SVR than with only SOF + RBV for 12 wk, although its association with more frequent adverse effects may be a limiting factor. Longer duration therapy with SOF + RBV (24 wk) has achieved higher SVR rates than shorter durations (12 or 16 wk). SOF + LDV are not an ideal treatment for genotype 3. CONCLUSION: Lastly, SOF + DCV combination is probably the best oral therapy option and the addition of RBV does not appear to be needed to increase SVR rates substantially.

引用

页码：5285 / 5292

页数：8

共 37 条

[1] SAFETY AND EFFECTIVENESS OF SOFOSBUVIR-BASED REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 3 AND 4 INFECTIONS: INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY [J].